Session Information
-
WCLC 2020
2020 World Conference on Lung Cancer
Conference Program for the 2020 World Conference on Lung Cancer in Singapore
Presentation Date(s):- January 28 - 31, 2021
- Total Presentations: 1597
All times listed are in Singapore time (GMT+8)
PL - Plenary
PS - Presidential Symposium
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
IS - Industry Symposium
JICC - Joint IASLC-CAALC-CSCO Session
January 28 Thu
Jan 28 Friday
January 29 Fri
Jan 29 Saturday
January 30 Sat
Jan 30 Sunday
January 31 Sun
Jan 31
-
+
P09 - Health Services Research/Health Economics - Real World Outcomes
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Health Services Research/Health Economics
-
+
P09.13 - Bone Metastases and Overall Survival in Patients with Metastatic Non-Small Cell Lung Cancer Treated with Pembrolizumab
00:00 - 00:00 | Presenter: Parthib Das
- Abstract
Loading...
-
+
P21 - Locoregional and Oligometastatic Disease - Treatment of Locally Advanced NSCLC
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Locoregional and Oligometastatic Disease
-
+
P21.02 - Incidence and Outcomes of Brain Metastases in Unresectable Stage III Patients with NSCLC Treated with Durvalumab after Chemoradiation
00:00 - 00:00 | Presenter: Sandip H Patel
- Abstract
Loading...
-
+
P48 - Small Cell Lung Cancer/NET - Chemo - IO
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Small Cell Lung Cancer/NET
-
+
P48.19 - Outcomes of Patients Treated with First Line Immunotherapy Plus Chemotherapy for ES-SCLC: Real World Outcomes from a Tertiary Academic Center
00:00 - 00:00 | Presenter: Sandip H Patel
- Abstract
Loading...
-
+
P75 - Immunotherapy (Phase II/III Trials) - Misc. Topics
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P75.12 - Prognostic Value of Neutrophil to Lymphocyte Ratio in NSCLC Patients Receiving First Line Immune Checkpoint Inhibitor Therapy
00:00 - 00:00 | Presenter: Nitya Surya
- Abstract
Loading...
-
+
P78 - Immunotherapy (Phase II/III Trials) - Immune Checkpoint Inhibitor Single Agent
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P78.05 - Patterns of irAE During First Line Pembrolizumab for NSCLC: Incidence, Risk Factors, and Impact on Clinical Outcome
00:00 - 00:00 | Presenter: Cameron Champion Wood
- Abstract
Loading...
-
+
P79 - Immunotherapy (Phase II/III Trials) - Immunotherapy Plus Chemotherapy
- 00:00 - 00:00
- 1/28/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Immunotherapy (Phase II/III Trials)
-
+
P79.04 - A Phase 2 Trial of Nivolumab and Temozolomide in Extensive Stage Small Cell Lung Cancer: Interim Efficacy Analysis.
00:00 - 00:00 | Presenter: Dwight H Owen
- Abstract
Loading...